Journal of Digestive Cancer Reports

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지
DOI QR코드

DOI QR Code

What are the Appropriate Surgery and Postoperative Surveillance for Intraductal Papillary Mucinous Neoplasm?

  • Ideno, Noboru (Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University) ;
  • Nakata, Kohei (Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University) ;
  • Nakamura, Masafumi (Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University)
  • Received : 2021.05.16
  • Accepted : 2021.05.24
  • Published : 2021.06.01
⟨ Previous Next ⟩

Abstract

Although many guidelines for pancreatic cystic neoplasms focus on the management of intraductal papillary mucinous neoplasm of the pancreas (IPMN) at the highest oncological risk, there are many issues that surgeons need to consider at the time to plan the surgical procedures based on characteristics of IPMN subtypes, such as multiplicity of branch duct-IPMN (BD-IPMN) and intraductal spreading of main duct-IPMN (MD-IPMN). For multifocal BD-IPMN, partial pancreatectomy would be selected to remove BD-IPMN with predictors of malignancy, while the other lesions without risk factors can be left, although total pancreatectomy might be considered if the patients have a strong family history of pancreatic cancer. Partial pancreatectomy would be also adequate procedure for MD-IPMN if negative surgical margin for high-grade dysplasia or invasive carcinoma were achieved. It has become to be well-known that patients with BD-IPMN are at increased risk for developing not only IPMN-associated pancreatic ductal adenocarcinoma (PDAC) but also PDAC independent from the IPMN. Hence, the detection of a concomitant PDAC is also an important focus for strategies after resection of BD-IPMNs. Our recent analysis of patients after partial pancreatectomy for MD-IPMN with negative surgical margin identified an unexpected recurrence pattern, which we called "monoclonal skip" recurrence. MD-IPMN seems to be disseminated in the pancreatic ductal systems and MD-IPMN with identical genetic background was detected in the remnant pancreas even in a long time after index surgery. We proposed strategies of postoperative surveillance based on characteristics and natural history of each morphological subtype.

Keywords

References

  1. Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017;17:738-753. https://doi.org/10.1016/j.pan.2017.07.007
  2. Basturk O, Hong SM, Wood LD, et al. A revised classification system and recommendations from the Baltimore Consensus Meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 2015;39:1730-1741. https://doi.org/10.1097/PAS.0000000000000533
  3. Miyasaka Y, Ohtsuka T, Tamura K, et al. Predictive factors for the metachronous development of high-risk lesions in the remnant pancreas after partial pancreatectomy for intraductal papillary mucinous neoplasm. Ann Surg 2016;263:1180-1187. https://doi.org/10.1097/SLA.0000000000001368
  4. Mino-Kenudson M, Fernandez-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 2011;60:1712-1720. https://doi.org/10.1136/gut.2010.232272
  5. Yopp AC, Katabi N, Janakos M, et al. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg 2011;253:968-974. https://doi.org/10.1097/SLA.0b013e318214bcb4
  6. Hirono S, Shimizu Y, Ohtsuka T, et al. Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society. J Gastroenterol 2020;55:86-99. https://doi.org/10.1007/s00535-019-01617-2
  7. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004;239:788-797; discussion 797-799. https://doi.org/10.1097/01.sla.0000128306.90650.aa
  8. Furukawa T, Hatori T, Fujita I, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 2011;60:509-516. https://doi.org/10.1136/gut.2010.210567
  9. European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 2018;67:789-804. https://doi.org/10.1136/gutjnl-2018-316027
  10. Vege SS, Ziring B, Jain R, Moayyedi P; Clinical Guidelines Committee; American Gastroenterology Association. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 2015;148:819-822; quize812-813. https://doi.org/10.1053/j.gastro.2015.01.015
  11. Oyama H, Tada M, Takagi K, et al. Long-term risk of malignancy in branch-duct intraductal papillary mucinous neoplasms. Gastroenterology 2020;158:226-237.e225. https://doi.org/10.1053/j.gastro.2019.08.032
  12. Schmidt CM, White PB, Waters JA, et al. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg 2007;246:644-651; discussion 651-654. https://doi.org/10.1097/SLA.0b013e318155a9e5
  13. Rodriguez JR, Salvia R, Crippa S, et al. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 2007;133:72-79; quiz 309-310. https://doi.org/10.1053/j.gastro.2007.05.010
  14. Waters JA, Schmidt CM, Pinchot JW, et al. CT vs MRCP: optimal classification of IPMN type and extent. J Gastrointest Surg 2008;12:101-109. https://doi.org/10.1007/s11605-007-0367-9
  15. Mori Y, Ohtsuka T, Kono H, et al. Management strategy for multifocal branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2012;41:1008-1012. https://doi.org/10.1097/MPA.0b013e31824b22c6
  16. Matthaei H, Norris AL, Tsiatis AC, et al. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2012;255:326-333. https://doi.org/10.1097/SLA.0b013e3182378a18
  17. Shi C, Klein AP, Goggins M, et al. Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009;15:7737-7743. https://doi.org/10.1158/1078-0432.CCR-09-0004
  18. Bartsch DK, Dietzel K, Bargello M, et al. Multiple small "imaging" branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia? Fam Cancer 2013;12:89-96. https://doi.org/10.1007/s10689-012-9582-y
  19. Skaro M, Nanda N, Gauthier C, et al. Prevalence of germline mutations associated with cancer risk in patients with intraductal papillary mucinous neoplasms. Gastroenterology 2019;156:1905-1913. https://doi.org/10.1053/j.gastro.2019.01.254
  20. He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg 2013;216:657-665; discussion 665-667. https://doi.org/10.1016/j.jamcollsurg.2012.12.026
  21. Kang CM, Choi SH, Kim SC, Lee WJ, Choi DW, Kim SW. Predicting recurrence of pancreatic solid pseudopapillary tumors after surgical resection: a multicenter analysis in Korea. Ann Surg 2014;260:348-355. https://doi.org/10.1097/sla.0000000000000583
  22. Dhar VK, Merchant NB, Patel SH, et al. Does surgical margin impact recurrence in noninvasive intraductal papillary mucinous neoplasms?: a multi-institutional study. Ann Surg 2018;268:469-478. https://doi.org/10.1097/SLA.0000000000002923
  23. Marchegiani G, Mino-Kenudson M, Sahora K, et al. IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann Surg 2015;261:976-983. https://doi.org/10.1097/SLA.0000000000000813
  24. Tamura K, Ohtsuka T, Ideno N, et al. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review. Ann Surg 2014;259:360-368. https://doi.org/10.1097/SLA.0b013e3182a690ff
  25. Hara T, Yamaguchi T, Ishihara T, et al. Diagnosis and patient management of intraductal papillary-mucinous tumor of the pancreas by using peroral pancreatos-copy and intraductal ultrasonography. Gastroenterology 2002;122:34-43. https://doi.org/10.1053/gast.2002.30337
  26. Nagayoshi Y, Aso T, Ohtsuka T, et al. Peroral pancreatoscopy using the SpyGlass system for the assessment of intraductal papillary mucinous neoplasm of the pancreas. J Hepatobiliary Pancreat Sci 2014;21:410-417. https://doi.org/10.1002/jhbp.44
  27. Ohtsuka T, Gotoh Y, Nakashima Y, et al. Role of Spy-Glass-DSTM in the preoperative assessment of pancreatic intraductal papillary mucinous neoplasm involving the main pancreatic duct. Pancreatology 2018;18:566-571. https://doi.org/10.1016/j.pan.2018.04.012
  28. Schnelldorfer T, Sarr MG, Nagorney DM, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg 2008;143:639-646; discussion 646. https://doi.org/10.1001/archsurg.143.7.639
  29. Miller JR, Meyer JE, Waters JA, et al. Outcome of the pancreatic remnant following segmental pancreatectomy for non-invasive intraductal papillary mucinous neoplasm. HPB (Oxford) 2011;13:759-766. https://doi.org/10.1111/j.1477-2574.2011.00354.x
  30. Moriya T, Traverso W. Fate of the pancreatic remnant after resection for an intraductal papillary mucinous neoplasm: a longitudinal level II cohort study. Arch Surg 2012;147:528-534.
  31. Frankel TL, LaFemina J, Bamboat ZM, et al. Dysplasia at the surgical margin is associated with recurrence after resection of non-invasive intraductal papillary mucinous neoplasms. HPB (Oxford) 2013;15:814-821. https://doi.org/10.1111/hpb.12137
  32. Pea A, Yu J, Rezaee N, et al. Targeted DNA sequencing reveals patterns of local progression in the pancreatic remnant following resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg 2017;266:133-141. https://doi.org/10.1097/SLA.0000000000001817
  33. Hirono S, Kawai M, Okada K, et al. Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas. Surgery 2016;160:306-317. https://doi.org/10.1016/j.surg.2016.04.007
  34. Rezaee N, Barbon C, Zaki A, et al. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. HPB (Oxford) 2016;18:236-246. https://doi.org/10.1016/j.hpb.2015.10.010
  35. Al Efishat M, Attiyeh MA, Eaton AA, et al. Progression patterns in the remnant pancreas after resection of noninvasive or micro-invasive intraductal papillary mucinous neoplasms (IPMN). Ann Surg Oncol 2018;25:1752-1759. https://doi.org/10.1245/s10434-018-6445-2
  36. Date K, Ohtsuka T, Fujimoto T, et al. Molecular evidence for monoclonal skip progression in main duct intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2017;265:969-977. https://doi.org/10.1097/SLA.0000000000001755
  37. Ingkakul T, Sadakari Y, Ienaga J, Satoh N, Takahata S, Tanaka M. Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg 2010;251:70-75. https://doi.org/10.1097/SLA.0b013e3181c5ddc3
  38. Yamaguchi K, Kanemitsu S, Hatori T, et al. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 2011;40:571-580. https://doi.org/10.1097/MPA.0b013e318215010c
  39. Ideno N, Ohtsuka T, Kono H, et al. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg 2013;258:141-151. https://doi.org/10.1097/sla.0b013e31828cd008
  40. Kobayashi G, Fujita N, Maguchi H, et al. Natural history of branch duct intraductal papillary mucinous neoplasm with mural nodules: a Japan Pancreas Society multicenter study. Pancreas 2014;43:532-538. https://doi.org/10.1097/MPA.0000000000000080
  41. Matsuda R, Miyasaka Y, Ohishi Y, et al. Concomitant intraductal papillary mucinous neoplasm in pancreatic ductal adenocarcinoma is an independent predictive factor for the occurrence of new cancer in the remnant pancreas. Ann Surg 2020;271:941-948. https://doi.org/10.1097/SLA.0000000000003060
  42. Ohtsuka T, Tanaka M. Postoperative surveillance of main duct IPMN. In: Tanaka M, ed. Intraductal papillary mucinous neoplasm of the pancreas. Tokyo: Springer, 2014:181-188.
  43. Ohtsuka T, Tanaka M. Postoperative surveillance of branch duct IPMN. In: Tanaka M, ed. Intraductal papillary mucinous neoplasm of the pancreas. Tokyo: Springer, 2014:189-199.